|
Bullish On Halozyme With Short Term Catalysts And Large Buy By A Jazz …
Trefis The second therapy is MabThera SC, or Rituximab, with trade name Rituxan. Rituxan was approved in the US in 1997 for the treatment of non-Hodgkin’s lymphoma. With validation of the approval of the monoclonal antibody Herceptin SC, it’s looking like … |
Monthly Prescribing Reference |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED : FDA Approves Teva’s …
4-traders (press release) TREANDA is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia … New Treanda Formulation ApprovedMonthly Prescribing Reference FDA approves Teva’s injectable TreandaGlobes |
|
FDA approves Teva’s injectable Treanda
Globes … (FDA) has approved a new injectable version Treanda for treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and chronic lymphocytic leukemia. |
|
Teva’s (TEVA) TREANDA Approved by US FDA
StreetInsider.com (subscription) TREANDA is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia … |
|
FDA Approves Teva’s TREANDA(R) (bendamustine HCI) Injection, a New Liquid …
MarketWatch TREANDA is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia … |
|
Halozyme Therapeutics, Inc. (HALO): Bullish On Halozyme: Short-Term …
Seeking Alpha The second therapy is MabThera SC, or Rituximab, with trade name Rituxan. Rituxan was approved in the US in 1997 for the treatment of non-Hodgkin’s lymphoma. With validation of the approval of the monoclonal antibody Herceptin SC, it’s looking like … |
Avacta Appoints New R&D Chief For Affimer Antibodies AlternativeLondon South EastAvacta acquired the intellectual property rights to Affimer – an alternative to the antibodies widely used in life-sciences research, diagnostics and therapeutics – in…
|
Multiple Sclerosis Therapeutics to 2019 – Treatment Diversification …
Sacramento Bee … 40 4.5.3 Laquinimod (laquinimod sodium) – Teva Pharmaceuticals 41 4.5.4 ocrelizumab – F. Hoffman-La Roche 42 4.5.5 daclizumab – Biogen Idec and Abbot Laboratories 42 4.5.6 firategrast – GlaxoSmithKline 43 4.5.7 Siponimod (BAF-312) – Novartis AG … |
|
Multiple Sclerosis Therapeutics to 2019 – Treatment Diversification …
The Herald | HeraldOnline.com … 40 4.5.3 Laquinimod (laquinimod sodium) – Teva Pharmaceuticals 41 4.5.4 ocrelizumab – F. Hoffman-La Roche 42 4.5.5 daclizumab – Biogen Idec and Abbot Laboratories 42 4.5.6 firategrast – GlaxoSmithKline 43 4.5.7 Siponimod (BAF-312) – Novartis AG … |
Management of Marginal Zone LymphomaCancer NetworkThere are several different treatment approaches for SMZL, including single-agent rituximab, splenectomy, and traditional chemotherapy. Tsimberidou et al evaluated rituximab with or without chemotherapy…